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Abstract
The effect of oestrogen replacement therapy (ERT) on stroke incidence and severity has been
extensively debated. Clinical trials of ERT have demonstrated an increased risk of stroke in treated
women, although the study participants were well past menopause when therapy was initiated. It
has been suggested that detrimental effects of ERT may be unmasked after prolonged periods of
hypoestrogenicity. To date, very few studies have examined the effect of ERT in aged animals,
although the timing of replacement may be critical to the neuroprotective effects of ERT. We
hypothesised that chronic ERT initiated in late middle age would decrease infarct size in the brain
after an induced stroke, whereas acute ERT would have no beneficial effects in aged females. To
test this hypothesis, two paradigms of ERT were administered to aged mice of both sexes aiming
to determine the effects on stroke outcome and to explore the possible mechanisms by which ERT
interacts with age. Female mice that received chronic ERT from 17–20 months of age showed
improved stroke outcomes after experimental stroke, whereas females that had acute ERT initiated
at 20 months of age did not. Chronic ERT females exhibited diminished levels of nuclear factor
kappa B (NF-κB) translocation compared to acute ERT females after stroke. Acute ERT females
demonstrated both an increase in nuclear NF-κB and enhanced expression of pro-inflammatory
cytokines. In addition, a sexual dimorphic effect of ERT was seen because males benefited from
ERT, regardless of the timing of initiation. Aged males had significantly reduced expression of
pro-inflammatory markers after stroke compared to age-matched females, suggesting a pro-
inflammatory milieu emerges with age in females. These results are consistent with the emerging
clinical literature suggesting that ERT should be initiated at the time of menopause to achieve
beneficial effects. The present study demonstrates the importance of using appropriate animal
models in preclinical studies.
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Stroke is a disease that mainly affects the elderly. Stroke rates more than double every 10
years after the age of 55 years in both men and women (1). However, functional outcomes
after stroke are worse in women than in men, with higher associated disability and mortality
(2). Most international databases consistently demonstrate that women enjoy a lower
incidence of stroke relative to men until well after menopause, after which stroke incidence
in women climbs dramatically (3, 4). Although the age-related risk of stroke is evident, very
few studies have examined the neurochemical changes that occur in aged brains after stroke
because most of studies have been exclusively performed in young animals.
Oestrogens, primarily 17β-oestradiol (E2), are potent neuroprotective agents in various
animal models, including experimental ischaemic stroke (5). Numerous observational and
retrospective clinical studies have also suggested that oestrogen replacement therapy (ERT)
protects postmenopausal women against age-related diseases, including cardiovascular
disease and stroke (6). However, two important clinical ERT trials, the Women Estrogen
Stroke Trial (WEST) and the Women Health Initiative (WHI) trial, reported an unexpected
increase in stroke incidence in E2-treated women (7, 8). The explanation for these findings
has been debated extensively in the literature (9). One major factor is the timing of E2
replacement. Participants recruited in these trials were well beyond menopause when they
received ERT; and it has been hypothesised that ERT should be initiated immediately at
menopause to achieve its protective effects (10, 11), which is an effect recently modelled in
preclinical studies. Prolonged periods of hypo-oestrogenicity led to an enhanced
inflammatory response when ERT was administered, which exacerbated stroke damage;
however, animals in that study were not aged. Intriguingly, the latest study (12) reporting on
post-intervention outcomes in women involved in the WHI trial who were taken off ERT
found that, after 10.7 years of follow-up, there was no significant difference in stroke risk
between E2 and placebo-treated groups.
Recent studies (13, 14) have revealed that brain ischaemia is a powerful stimulus that
triggers a series of events leading to the activation of several transcription factors involved
in the inflammatory responses, including nuclear factor kappa B (NF-κB) (15). After
ischaemia NF-κB translocates from the cytoplasm to the nucleus and up-regulates the
expression of many pro-inflammatory genes, such as tumour necrosis factor (TNF)-α,
monocyte chemotactic protein (MCP)-1 and interlukin (IL)-6, etc. (15, 16). A growing body
of evidence (17, 18) has shown that E2 interacts with NF-κB through oestrogen receptor
(ER)α to down-regulate the expression of inflammatory cytokines. However, whether E2
continues to have these beneficial effects in the aged brain is not yet known.
The present study aimed to evaluate the effects of either chronic or acute ERT on aged mice
subjected to ischaemic stroke and to explore the possible mechanism underlying the effects
of E2 in the aged brain. The mice utilised in the present study were 17 months old, which is
an age equivalent to a 50–55-year-old woman (19) (i.e. the approximate age of menopause).
We hypothesised that only chronic ERT initiated early after reproductive senescence would
exert neuroprotective effects on mice after stroke, and predicted that the effect is related to
the down-regulation of NF-κB activation as a result of continuous exposure to E2 after
menopause. We also performed studies in aged males, aiming to determine whether there
were sex differences in the response to ERT and to control for other factors associated with
ageing.
Materials and methods
Animals
C57BL / 6 mice (17 months old) of both sexes were purchased from the NIA aged mouse
colony (Charles River Laboratories, San Diego, CA, USA) All experiments were performed
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in accordance with NIH guidelines for the care and use of animals in research and under
protocols approved by the UCHC Animal Care and Use Committee.
E2 replacement
E2 replacement was administered by implanting E2 pellets s.c. as described previously (20).
Briefly, E2 was delivered s.c. by a silastic capsule (0.062 inch inner diameter; 0.125 inch
outer diameter) filled with 0.035 ml of E2 (180 mg / ml; Sigma, St Louis, MO, USA) in
sesame oil or sesame oil alone (vehicle). Two protocols for E2 pellet replacement were
developed: for chronic ERT, pellets were implanted in mice at 17 months of age and
replaced every month until 20 months of age; for acute ERT, E2 pellets were only implanted
once, at 20 months of age. Mice were exposed to anaesthesia at the same frequency as that
of the chronic ERT mice to control for repeated anaesthetic effects. Mice from both groups
were then subjected to ischaemic stroke at 20.5 months (Fig. 1). Control groups were treated
with sesame oil pellets replacement therapy (ORT) correspondingly (chronic or acute ORT).
Animals were randomised into treatment groups and stroke was performed by a blinded
investigator.
Focal cerebral ischaemic model
Focal transient cerebral ischaemia was induced by reversible middle cerebral artery
occlusion (MCAO) for 90 min followed by reperfusion as described previously (20). A 6–0
nylon suture, 0.23 mm in dimension, was utilised to occlude the MCA. During surgery and
ischaemia, rectal muscle temperature was monitored with a Monotherm system (V WR
LabShop, Batavia, IL, USA) and maintained at approximately 37 °C with an automated
temperature control feedback system; after surgery, the mice were returned into a cage with
a heating pad system that maintained temperature until reperfusion. Cerebral blood flow was
measured by Laser Doppler flowmetry (LDF; Moor Instruments Ltd, Axminster, UK) for
every single mouse. Occlusion was confirmed by a drop in LDF by 85% of baseline in all
mice. Neurological deficit scores were recorded 4 h after stroke and at sacrifice. The scoring
system was: 0, no deficit; 1, forelimb weakness and torso turning to the ipsilateral side when
held by tail; 2, circling to affected side; 3, unable to bear weight on affected side; 4, no
spontaneous locomotor activity or barrel rolling. All mice were examined before MCAO for
dermatitis or visible tumours and were subjected to necropsy after sacrifice to exclude any
animals with gross tumours including those in the pituitary region or other visible
comorbidities.
Histological assessment
For evaluation of stroke outcomes, the mice were allowed to survive for 24 h and then were
sacrificed with pentobarbital overdose (i.p.). Animals were perfused transcardially with cold
phosphate-buffered saline followed by 4% paraformaldehyde; the brain was removed from
the skull and post-fixed for 18 h and subsequently placed in cyroprotectant (30% sucrose).
The brain tissue was cut into 30-μm free-floating coronal sections on a freezing microtome
and every eighth slice was stained by cresyl violet (CV) staining for evaluation of ischaemic
cell damage (21). Then images were digitalised by a charge-coupled device camera
(Qiamging, Surrey, BC, Canada), and the infarct volumes [expressed as a percentage of (%)
the contralateral hemispheric structure to correct for oedema] (Swanson’s method) (22) and
analysed using SIGMASCAN PRO5 (Systat Software Inc., Chicago, IL, USA) as described
previously (20).
Subcellular fractionation
For analysis of protein expression, subcellular fractionation was performed as described
previously (23). Briefly, brain samples were obtained by rapid removal of the brain, with the
Liu et al. Page 3
J Neuroendocrinol. Author manuscript; available in PMC 2013 February 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
subsequent removal of the cerebellum / occipital pole and olfactory / frontal pole to enrich
for tissue supplied by the MCA. The ipsilateral hemispheres were homogenised in Dounce
homogenisers with cold lysis solution [50 mM HEPES, pH 7.5, 1 mM ethylenediamine
tetraacetic acid (EDTA), 1 mM ethylene glycol tetraacetic acid (EGTA), 50 mM NaF, 0.25
mM sucrose, 1 mM dithiothreitol, Protease cocktail (dilution 1 : 50; Roche Diagnostics
Corp., Basel, Switzerland)]. Homogenates were filtered and centrifuged at 800 g for 10 min
at 4 °C. The pellet (P1) contained the nuclear fraction; the supernatant (S1) was further
centrifuged at 15 000 g for 10 min to obtain the cytosolic (supernatant, S2) and the
mitochondrial fraction (pellet, P2). The P2 pellet was washed in SEE buffer [10 mM
HEPES, pH 7.4, 1 mg / ml bovine serum albumin (BSA), 0.5 mM EDTA, pH 8.0, 0.5 mM
EGTA, pH 8.0], then centrifuged at 15 000 g for 10 min. The S2 supernatant (cytosolic
fraction) was centrifuged at 20 200 g for 30 min. The resulting supernatant is the cytosolic
fraction. The P1 pellet was resuspended in a Tris buffer and run through a sucrose gradient
composed of 1.8 and 2.3 M sucrose and centrifuged in a SW41 rotor at 30 000 g for 45 min.
The pellet (P3) was washed with a nuclei pure storage buffer (Sigma-Aldrich, St Louis, MO,
USA), and centrifuged at 960 g for 10 min. The pellet (P4) was resolved with nuclear
extraction buffer (20 mM HEPES, pH 7.9, with 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM
EDTA and 25% glycerol) (Sigma-Aldrich), sonicated, and stored at −80 °C as the nuclear
fraction.
Western blots
The fractionated protein concentration was determined by BCA Protein Assay Kit (Thermo
Fisher Scientific Inc., Rockford, IL, USA) and subjected to western blotting as described
previously (23). Sample proteins were resolved on 4–15% sodium dodecylsulphate
electrophoresis gels and transferred to a polyvinylidene fluoride membrane and then probed
with NF-κB (p65; dilution 1 : 1000; Abcam, Cambridge, MA, USA), ERα (dilution 1 : 500;
Abcam), insulin-like growth factor (IGF)-1 receptor β (IGF-1Rβ) (dilution 1 : 1000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and Bcl-2 (dilution 1 : 500; Cell Signaling
Technology, Beverly, MA, USA). Macrophage migration inhibitory factor (MIF; dilution 1 :
1000; Cell Sciences, Canton, MA, USA) and Histone H3 (dilution 1 : 4000; Abcam) were
used as loading controls for cytosolic and nuclear fractions, respectively. All blots were
incubated overnight in primary antibodies at 4 °C in Tris-buffered saline containing 4%
BSA and 0.1% Tween 20. Secondary antibodies (goat anti-rabbit IgG, dilution 1 : 5000; goat
anti-mouse IgG, dilution 1 : 5000; donkey anti-goat IgG, dilution 1 : 1000; Santa Cruz
Biotechnology) were diluted and ECL detection kit (Amersham Pharmacia, Piscataway, NJ,
USA) was used for signal detection. Densitometry of western blots was analysed with
SCION IMAGE (Scion Corp., Frederick, MD, USA) as described previously (20).
Immunhistochemistry (IHC)
Floating brain sections were prepared as described previously (24). Briefly, free-floating
sections were blocked in normal goat serum block solution (PBTGS buffer: phosphate
buffer + 0.3% Triton X-100 + 10% goat serum) for 1 h at room temperature followed by
incubation overnight at room temperature with primary antibodies diluted with PBTGS
buffer: anti-NF-κB p65 (dilution 1 : 200; Abcam); anti-neuronal nucleus (NeuN) (dilution
1 : 200; Chemicon International Inc., Temecula, CA, USA). The secondary antibodies
(dilution 1 : 1000; Invitrogen, Carlsbad, CA, USA) were tagged with red or green
fluorescent Fluor dye and diluted in PBTGS buffer. They were either goat anti-mouse or
goat anti-rabbit depending on the primary antibody and were incubated for 2 h at room
temperature. 4′,6-diamidino-2-phenylindole (DAPI) (dilution 1 : 1000; Invitrogen) was
added to the sample together with the secondary antibodies. The signal was visualised with a
Zeiss Axiovert 200M microscope (Carl Zeiss, Oberkochen, Germany) using a X-Cite 120Q
fluorescence illumination system (Lumen Dynamics Group Inc., Mississauga, ON, Canada)
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using Zeiss image acquisition software (Zeiss LSM 510). All slices (from the same brain as
for CV staining) were approximately 0.5 mm anterior to bregma and three × 20 fields /
animal (n = 6 animals per group) were analysed in the penumbral area of the infarct. Cells
with NF-κB and NeuN co-localised in the nuclei were counted using
MACBIOPHOTONICS IMAGEJ software (http://www.macbiophotonics.ca) after a DAPI
counterstain to confirm nuclear localisation. For each animal, the total numbers of cells in
three × 20 fields were used for the statistical analysis.
E2, testosterone and cytokine analysis
Serum levels of E2, testosterone, MCP-1, IL-6 and TNF-α were measured in each group by
enzyme-linked immunosorbent assay (ELISA) (E2; IBL Hamburg, Hamburg, Germany;
testosterone; Calbiotech, Spring Valley, CA, USA; MCP-1, IL-6, TNF-α; eBioscience, San
Diego, CA, USA). The uterus was removed at sacrifice in all female mice and weighed at
sacrifice to confirm the loss of end-organ oestrogen effects.
Statistical analysis
Data from individual experiments are presented as the mean ± SEM and analysed with a t-
test for two groups, and two-way ANOVA (with Tukey’s post-hoc correction for multiple
comparisons where appropriate) for the comparison of the means between the experimental
groups. Neurological deficit scores were analysed with a Mann–Whitney U-test. P < 0.05
was considered statistically significant. Induction of ischaemia and all behavioural and
histological assessments were performed by an investigator who was blinded to vehicle or
E2 replacement.
Results
Chronic and acute ERT exerted different effects on stroke outcomes in males and females
To evaluate the effects of E2 replacement initiated at different times during the lifespan on
ischaemic stroke, we designed two experimental paradigms: chronic and acute ERT (Fig. 1).
We first measured stroke outcome 24 h after the induction of a 90-min MCAO. Brain slices
were stained with CV and infarct volumes were digitally calculated (Fig. 2A–D). Consistent
with our previous study performed in middle-aged mice (20), both chronic or acute ORT
males had significantly smaller infarct volumes than their counterpart females. Both chronic
and acute ERT decreased infarct volumes significantly in males compared to vehicle-treated
groups (total infarct: chronic ERT versus chronic ORT 15.1 ± 3.1% versus 33.2 ± 2.0%,
acute ERT versus acute ORT 16.4 ± 2.9% versus 34.4 ± 3.1%; n = 12 per group, P < 0.05).
A different pattern was seen in females. Only chronic ERT reduced infarct volume
compared to oil-treated mice (total infarct: chronic ERT versus chronic ORT 34.7 ± 2.4%
versus 58.2 ± 2.6%; n = 9 per group, P < 0.05) and there was no difference in infarct size
between acute ERT and ORT groups (total infarct: acute ERT versus acute ORT 57.8 ±
1.8% versus 64.1 ± 2.4%; n = 10 per group, P > 0.05). Neurological deficit scores reflected
these changes in infarct size (Fig. 2E). There were no differences in preischaemic or
intraischaemic arterial blood pressure, and blood gas measurements between any two
groups; however, female mice in both the ORT and chronic ERT groups were significantly
lighter than their male counterparts (n=6 per group, P < 0.05) (See Table 1).
NF-κB translocation differed between the sexes after MCAO
With ischaemic injury, NF-κB is activated and translocates from the cytosol to the nucleus
to regulate gene expression of inflammatory cytokines (15). To examine the translocation of
NF-κB, we performed immunofluorescent staining to co-label brain slices with NF-κB and
NeuN. Because NeuN is also expressed in cytoplasm (25, 26), we further exposed the slices
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with the nuclear stain, DAPI, to confirm the nuclear localisation of NF-κB. As shown in Fig.
3(A), NF-κB co-labelled with NeuN in the nucleus in stroke brains (NF-κB translocation
positive cells; indicated by arrows in the upper panel of Fig. 3A); however, in sham brains,
NF-κB was localised only in the cytoplasm (NF-κB translocation negative cells; indicated
by arrow heads in the lower panel of Fig. 3A). Quantification was performed in all the
stroke groups (Fig. 3B–D). There were significantly less NF-κB translocation positive cells
in chronic ORT or acute ORT males compared to their counterpart females, and ERT did not
decrease NF-κB translocation significantly in males. Interestingly, chronic ERT females had
significantly fewer positive cells than chronic ORT females; however, no difference in NF-
κB positive cell numbers was seen between acute ERT and ORT females.
Western blotting showed a reduction in NF-κB expression in chronic ERT females
To confirm the IHC findings, and quantify nuclear NF-κB expression levels, western
blotting was performed to examine nuclear NF-κB expression. Consistent with the IHC data,
chronic ERT females had significantly less nuclear NF-κB compared to either chronic ORT
or acute ERT females (Fig. 4A–C). Acute ERT females exhibited higher NF-κB expression
in the nuclear fragment compared to acute ORT females. No significant difference in NF-κB
expression levels was seen between male cohorts.
Expression of pro-inflammatory cytokines differed after stroke in males and females
Because NF-κB can regulate the expression of IL-6, MCP-1 and TNF-α, etc., we next
examined the serum level of these cytokines by ELISA. We selected to assess cytokines 24
h after stroke. Proinflammatory signalling occurs in two peaks after stroke: the first peak is
usually within 6 h and the second peak occurs 24–36 h after stroke (27). Stroke induced a
significant increase in levels of these cytokines in every group compared to sham (see
Supporting information, Tables S1–S3). Both MCP-1 and IL-6 levels in chronic ERT
females were significantly lower than those in chronic ORT or acute ERT females; chronic
ERT also reduced TNF-α levels compared to chronic ORT females (Fig. 5A–C; n = 6 per
group, P < 0.05). In males, E2 treatment did not decrease these cytokines compared to oil
vehicle groups after stroke; however, chronic ORT or acute ORT males had significantly
lower MCP-1 compared to their counterpart females. IL-6 and TNF-α levels were
significantly lower in chronic ORT males compared to chronic ORT females.
Serum E2, testosterone levels and uterine weights
Serum E2 and testosterone levels were assessed in each group by ELISA. As expected, both
chronic ERT or acute ERT paradigms led to significantly higher serum E2 levels compared
to those seen in the chronic ORT or acute ORT mice of both sexes (Fig. 6A), and were
equivalent to basal circulating oestrous levels of cycling female mice (28–30). No difference
in E2 levels were seen between chronic and acute ERT mice. Uterine weights in all female
mice showed the same pattern as serum E2 levels (Fig. 6B). The mean testosterone level was
below 1 ng / ml in all groups regardless of sexes, which is lower than the previously
reported levels in young C57BL6 male mouse (> 10 ng / ml) (31, 32), and showed no
significant differences between groups (see Supporting information, Fig. S1).
Effects of ERT on ERα, IGF-1Rβ, Bcl-2 expression
E2 replacement led to a higher expression of cytosolic ERα in both chronic ERT males and
females compared to their acute ERT counterparts after stroke. Intriguingly, acute ERT
decreased ERα levels after stroke compared to sham groups in both males and females (Fig.
7A,C). ERα levels in both male groups were significantly lower than their female
counterparts. E2 can also regulate the expression of the anti-apoptotic protein Bcl-2, by
interacting with IGF-1 (33). Therefore, we also examined IGF-1Rβ and Bcl-2 expression by
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western blotting. We found that these two protein levels significantly increased after stroke
in each group compared to sham mice, except for IGF-1Rβ in chronic ERT males (Fig.
7A,B) and Bcl-2 in acute ERT males (Fig. 7D,E); however, no significant differences were
seen between sexes and treatments.
Discussion
The present study demonstrates several important new findings. First, the timing of
administration of ERT is important, although only in the female brain. Both chronic ERT
and acute ERT led to neuroprotection after induced stroke in males; however, only chronic
ERT improved infarct outcome in females, whereas acute ERT did not. Oil-treated males
had significantly smaller infarcts than oil-treated females, which is consistent with previous
findings in middle-aged animals (20). Second, the expression of nuclear NF-κB was
different in males versus females after stroke. Male mice had less NF-κB translocation after
stroke compared to their counterpart females, except in the chronic ERT group. Chronic
ERT robustly inhibited NF-κB translocation in females after stroke compared to chronic
ORT females, which reduced the level to that of chronic ERT males; however, acute ERT
increased NF-κB translocation beyond that seen with acute ORT, consistent with the
proinflammatory effects of acute ERT. Third, the pro-inflammatory cytokines MCP-1, IL-6,
and TNF-α induced by NF-κB were inhibited by chronic ERT but not acute ERT in females.
Fourth, the timing of E2 therapy had an effect on expression of ERα after stroke (i.e. acute
ERT decreased, whereas chronic ERT increased, cytosolic ERα levels in both males and
females after stroke compared to shams). Two-way ANOVA also showed a sex effect in
ERα expression (i.e. females had significantly higher level of ERα compared to males in
each respective treatment group). Finally, although IGF-1 and Bcl-2 levels increased after
stroke in both male and female mice, neither sex, nor the timing of E2 therapy had an effect
on levels of either protein.
Extensive debate continues regarding the potential neuroprotective effects of E2 in both pre-
clinical and clinical populations (9); the importance of the timing therapy of ERT has been
increasingly recognised. The interval between menopause and the start of ERT plays a
crucial role in the effectiveness of ERT in the vascular system (34). The present study found
that only chronic ERT reduced infarct in aged females. We designed the chronic ERT
treatment to initiate ERT in mice beginning at an age equivalent to a 50–55-year-old woman
(19), the approximate age of menopause. Interestingly in both the WEST and WHI trial,
both of which showed an increase in stroke incidence in treated women, the mean age of the
participants at entry was 63 years (WHI) or 71 years (WEST), representing an age well past
menopause. In a previous study (12) where young female mice were ovariectomised (OVX),
it was found that E2 treatment was neuroprotective only if treatment was initiated
immediately after OVX, which is consistent with our results demonstrating that chronic ERT
was neuroprotective. If E2 treatment was delayed for 10 weeks after OVX, the infarct size
was significantly larger (12); however, in the present study, acute ERT had no effect in aged
females. The subtle difference between the previous and the present study may be a result of
the different menopausal models used. In the present study, we used intact aged mice (17
months old), which have low circulating E2, testosterone, and low uterine weights to model
natural menopause and to determine the effects of ERT in the ageing brain. By contrast, the
previous study was performed in young females after surgical menopause (11). Additionally,
we utilised a reperfusion injury, where the suture was removed after 90 min, allowing for
reperfusion, whereas a permanent occlusion model was used in the previous study. This
model leads to larger infarcts (35, 36) that may be less responsive to neuroprotectants (37)
compared to that of the reperfusion model. Previous studies of ERT in middle-aged rats
subjected to MCAO demonstrated similar results to those reported in the present study.
Immediate ERT after OVX decreased infarct volume in 9–12-month-old female rats (38),
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whereas ERT initiated after an additional 9 weeks of E2-deficiency significantly increased
infarct size (39). Intriguingly, long-term ovarian hormone deprivation not only blocks the
beneficial effects of ERT in ischaemic injury, but also attenuates the ability of E2 to improve
hippocampus-dependent memory in both young adult and middle-aged rats (40).
The mechanism by which E2 loses its protective effects after a prolonged period of
hypoestrogenicity is not yet known. E2 is known to have profound effects on inflammation,
which, in turn, can influence stroke outcome (41). In most cases, at least in models that have
examined young animals, E2 suppresses the inflammatory response. This occurs in central
nervous system disorders (42), as well as in models of arthritis (43), wound repair (44) and
trauma (45). However, the role E2 plays in inflammation is complex. It is becoming
increasingly clear that ERT administered at different time points during the lifespan can
elicit very different effects (46). This is evident in many species, including primates. In
surgically ovariectomised primates, a 70% reduction of atherosclerosis was seen when ERT
was initiated simultaneously with an atherosclerotic diet but, when ERT was delayed 2 years
after diet initiation, no protection against atherosclerosis was observed (47). The
inflammatory responses induced by NF-κB activation play crucial roles in the development
of post-stroke injury (48). E2 has long been known to inhibit NF-κB activity in various
diseases, including stroke (18, 49); the loss of E2 with menopause promotes a pro-
inflammatory state that is unmasked with acute injury. The present study revealed that
chronic, but not acute, E2 replacement suppresses this NF-κB proinflammatory response,
which likely contributes to the reduction of infarct volume after MCAO.
The timing effect of E2 on ischaemic stroke in aged mice also showed a subtle sexual
dimorphic effect in the present study. To date, no studies have examined the effects of ERT
after MCAO in aged mice. Young mice have been increasingly used in focal ischaemia
models as a result of the availability of transgenic and knockout strains (21). Only a few
studies on ischaemic stroke have been performed in aged rats (50–52), and the results from
these studies were quite controversial. This may be because of the variability of the sex of
the animals examined. Sex differences have been well documented in ischaemic stroke
studies using young animals (5, 23). The neuroprotective effects of E2 are a major
contributor to the smaller infarcts seen in young gonadally intact females. Numerous
neurochemical and physiological changes occur with ageing (53), which likely lead to
differences in ischaemic sexual dimorphism between young and aged animals. We have
previously found that middle-aged male mice (15 months) had significantly smaller infarct
volumes than females after MCAO (20), and the present study now extends these findings
into the aged brain. These findings are consistent with clinical data demonstrating that aged
women have higher disability and mortality than men after stroke (2). Despite the significant
difference in infarct in oil-treated groups, no difference in neurological deficits were seen
between males and females, suggesting that infarct size does not necessarily correlate with
behavioural deficits, especially in aged animals.
Inflammatory responses have long been known to contribute to ischaemic injury (14),
although how the inflammatory response changes with age and sex is not yet known. Serum
levels of IL-6 differed in middle-aged male and female mice after stroke (20), which we
investigated further in the present study. The expression of several pro-inflammatory
markers, NF-κB, MCP-1 and IL-6, were significantly up-regulated after stroke in females
compared to males. The higher level of pro-inflammatory markers is consistent with clinical
data (54) showing that women enjoy immunological and metabolic advantages until
menopause, which then decrease as women age. The results of the present study suggest that
differential inflammatory responses after stroke contribute, at least in part, to differences in
stroke outcomes in aged male and female mice.
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Chronic and acute ERT not only led to different stroke outcomes and inflammatory
responses, but also induced age-related differences in ERα expression. E2 receptor α (and
not β) is a critical to E2-mediated protection against brain injury (55) and was therefore the
focus of these investigations. Oestrogens are known to autoregulate ER (56), and the
expression of ERα increases greatky in the ischaemic cortex after stroke injury (41);
therefore, it is not unexpected that chronic ERT induced high levels of ERα in both male
and female mice after stroke. However, there was a different response of ERα to ERT in the
acute ERT groups, with decreased ERα expression in both sexes after stroke. It has been
reported that the expression of both ERα and ERβ decreases with age in the cortex and
hippocampus (57, 58), which could contribute to a decreased responsiveness to E2 in the
acute ERT groups. The results obtained in the present study suggest that the decreased
expression of ERα in aged animals cannot be reversed by acute ERT, in contrast to chronic
ERT. To counteract the decreased responsiveness caused by ageing, it may be necessary to
start E2 replacement early after menopause so that ER levels can be maintained. This is
suggested by our results demonstrating that chronic ERT groups of both sexes had increased
ERα expression compared to the corresponding acute ERT groups. The mechanism by
which ERα expression decreases with age has not been elucidated; however, a recent study
reported that methylation of 5′ untranslated exons in DNA encoding ERα increases with
age, leading to silencing of the ERα gene (59). Methylation of DNA is an epigenetic
mechanism underlying gene silencing (31). Interestingly, increased methylation of DNA
with age also exists in X-chromosome inactivation (XCI), a major mechanism for dosage
compensation of X-linked genes in females. XCI becomes unstable with ageing, and XCI
skewing may occur in ageing populations, as demonstrated by increasing levels of
methylation of target genes (60). Gene silencing by methylation of DNA in ageing subjects
is being increasingly recognised and requires further study.
Sex differences in ERα expression were also seen in the present study (i.e. males had
significantly lower cytosolic ERα level than females in each group), consistent with
previous studies (61, 62). Activation of ERα can have inhibitory effects on NF-κB activity
via enhancement of endogenous inhibitors of NF-κB, or by direct inhibition of NF-κB DNA
binding activity (17). This is consistent with our finding that chronic ERT female mice had
less nuclear NF-κB than that of acute ERT females, which also had lower levels of ERα
expression. However, acute ERT females, despite their higher ERα levels, had larger
infarcts than acute ERT males. This suggests that acute ERT is unable to inhibit NF-κB in
females despite the higher level of ERα expression, and demonstrates that ERα levels do
not correlate with infarct size. Both chronic and acute ERT males had low level of NF-κB,
although chronic ERT males had higher expression levels of ERα compared to acute ERT
males. However, both acute and chronic ERT were neuroprotective in males. The
complicated nature of the relationship between E2 signalling and NF-κB seen in aged male
animals suggested that E2 signalling may not be a major contributor to NF-κB activity in
males.
One major limitation of these results is that ERα levels were only measured in the cytosolic
fractions. Therefore, the results must be interpreted with caution. It is possible that acute E2
treatment led to receptor dimerisation with subsequent DNA binding and nuclear
translocation. Indeed, decreased levels of cytosolic ER could be secondary to nuclear
translocation and subsequent enhancement of ER signalling. However, it is clear that
differences exist in the response of the ER to both E2 treatment regimen and by sex. Further
studies that directly evaluate nuclear ER levels or, even more importantly, directly assess the
downstream consequences of ER activation in the aged stroke brain are needed. This will
require the use of ER knockout mice.
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Another important pathway through which E2 may exert its neuroprotective effects is via
interaction with IGF-1, leading to activation of the extracellular regulated kinase / mitogen-
activated protein kinase signalling cascade and activation of transcription factor such as
cAMP-response element binding protein, whose target genes include Bcl-2 (63, 64). In the
present study, both IGF-1Rβ and Bcl-2 were increased after stroke compared to sham in
each group, reflecting the activation of neuroprotective E2–IGF-1 axis. However, no
differences in the expression of these two proteins were seen between the acute and chronic
ERT groups of both sexes, indicating that sex differences and timing effects of E2 in
ischaemic stroke in aged mice are not caused by activity of E2–IGF-1 axis.
The present study has several limitations that must be kept in mind when interpreting the
results. MCAO in mice is not a perfect model to compare to the WHI trial because we
induced a stroke and infarct size was examined subsequently. This is very different from the
WHI trial in which the outcome assessed was stroke incidence. In the present study, we
administered ERT to mice before MCAO; however, in most clinical neuroprotection trials,
agents are usually applied a few hours after stroke onset. It is possible that E2 may be
equally effective in both sexes if administered as an acute neuroprotectant. We also only
evaluated acute stroke outcomes after 24 h of stroke; therefore, the long-term effects of ERT
in aged mice of both sexes remain unknown. However, previous work in this model has
shown that infarct is complete by 24 h (65) and infarct size at 24 h correlates well with that
seen at 30 days, even in aged mice (66).
In conclusion, the effect of ERT on stroke in aged mice is modulated by several factors.
Overall, sex differences are evident in that ERT led to neuroprotection in aged male mice
regardless of the timing of ERT; whereas the effect is modulated in aged females based on
the timing of initiation of therapy. Chronic ERT treated females showed improved stroke
outcomes, whereas acute ERT had no beneficial effect on stroke induced brain injury.
Inflammatory responses may mediate the differential effect of ERT in aged mice because
NF-κB translocation and serum levels of MCP-1, IL-6 and TNF-α paralleled the changes in
infarct size. ERα expression exhibited sex differences in aged mice after stroke, and may
contribute to the inflammatory response to ischaemic stroke in aged females.
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Fig. 1.
Schematic representation of the experimental design of 17β-oestradiol (E2) replacement. In
the chronic E2 replacement group, E2 pellets were first implanted to mice at 17 months old
and replaced every month until the twentieth month; in the acute E2 replacement group, the
pellets were only implanted in the twentieth month. Mice were subjected to MCAO 15 days
after the final implant of the pellets. Control groups used pellets that contain oil vehicle and
were treated with the same experimental conditions as the E2-treated groups.
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Fig. 2.
Effect of 17β-oestradiol (E2) replacement on infarct size in mice. (A) Representative image
of a cresyl violet (CV)-stained brain for each group. The area lacking staining (white)
reflects the infarct. (B–D) Quantification of infarct volumes based on CV staining in total
hemisphere (B), cortex (C) and striatum (D). (E) Neurological deficit scores at 4 h of stroke.
In all figures: *P < 0.05 versus oil-treated counterparts in males; **P < 0.05 versus chronic
vehicle or acute E2-treated female mice; n = 9–12 animals per group. ORT, oil pellets
replacement therapy; ERT, oestrogen replacement therapy.
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Fig. 3.
Immunofluorescence of nuclear factor kappa B (NF-κB), neuronal nucleus (NeuN) and 4′,6-
diamidino-2-phenylindole (DAPI). (A) Co-localisation of NF-κB and NeuN (NF-κB
translocation positive cells indicated as arrows; negative cells as arrow heads) in the nucleus
(upper panel; stroke groups) and the cytosol (lower panel; sham groups) (× 100
magnification; scale bar = 20 μm). (B,C) Co-labelling of NF-κB and NeuN in aged male (B)
and female (C) mice brain after stroke. Boxed areas in a cresyl violet stained slice illustrate
the three examined regions in each slice (× 20 magnification; scale bar = 50 μm). (D) Semi-
quantification of co-localisation of NF-κB and NeuN in the nucleus. Each column stands for
nine fields from six animals. *P < 0.05 versus oil or E2 counterparts in males. **P < 0.05
versus chronic oil or acute E2-treated group. ORT, oil pellets replacement therapy; ERT,
oestrogen replacement therapy.
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Fig. 4.
Nuclear factor kappa B (NF-κB) expression in the nucleus after stroke. (A) Representative
western blots of NF-κB protein levels in the nuclear fraction of brain homogenates from
male (right) and female (right) mice 24 h after stroke onset. Histone H3 was used as a
loading control and migration inhibitory factor (MIF) confirmed the lack of cytosolic
contamination. (B,C) The optical density of samples in males (B) and females (C) was
expressed as the ratio of NF-κB bands to control bands (Histone). Six stroke and six sham
brains were randomly aliquoted into three separate experiments for statistical analysis. *P <
0.05 versus stroke mice in acute oil pellets replacement therapy (ORT) group; **P < 0.05
versus stroke mice in acute oestrogen replacement therapy (ERT) or chronic ORT group. Sh,
sham; St, stroke.
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Fig. 5.
Serum levels of monocyte chemotactic protein (MCP)-1 (A), interleukin (IL)-6 (B) and
tumour necrosis factor (TNF)-α (C) after stroke. *P < 0.05 versus female counterparts; **P
< 0.05 versus chronic oil or acute 17β-oestradiol (E2)-treated group in females; ΔP < 0.05
versus chronic oil group in females (n = 6 per group).
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Fig. 6.
Serum levels of 17β-oestradiol (E2) and uterine weights after middle cerebral artery
occlusion. (A) Serum E2 levels in stroke mice. *P < 0.05 versus E2-treated counterparts in
males. **P < 0.01 versus E2-treated counterparts in females (n = 6 per group). (B) Uteruses
of both oil and E2-treated female mice were separated, cut, and weighed after brains were
removed. All the uteruses were handled and measured by the same investigator (n = 6 per
group). *P < 0.05 versus E2-treated counterparts.
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Fig. 7.
Western blots of inslulin-like growth factor (IGF)-1Rβ, oestrogen receptpr (ER)α and Bcl-2
in each group. (A) Expression of IGF-1Rβ and ERα in the cytosolic fraction of brain
homogenates from E2-treated male and female mice 24 h after stroke onset. Migration
inhibitory factor (MIF) was used as a loading control and Histone H3 analysis confirmed the
lack of nuclear contamination. (B,C) The optical density of samples in (A) was expressed as
the ratio of IGF-1Rβ (B) and ERα (C) bands to control bands (MIF). (B) *P < 0.05 versus
sham groups. (C) *P < 0.05 versus acute sham groups; **P < 0.05 versus chronic sham
groups. (D) Expression of Bcl-2 in the cytosolic fraction of brain homogenates from E2-
treated male and female mice 24 h after stroke onset. MIF was used as a loading control and
Histone H3 confirmed the lack of nuclear contamination. (E) The optical density of samples
in (D) was expressed as the ratio of Bcl-2 bands to control bands (MIF). *P < 0.05 versus
sham groups. Six stroke and sham brains were randomly aliquoted into three separate
experiments for statistical analysis. Sh, sham; St, stroke.
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